ALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

BURLINGAME, Calif., March 02, 2021 – ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced participation in a fireside chat at H.C. Wainwright’s Global Life Sciences Conference on March 9-10, 2021. Jaume Pons, Ph.D., and senior executives will provide insights during the virtual event. A prerecorded chat is set to release on March 9, 2021, at 7:00 a.m. Eastern Time, accessible via ALX Oncology's website. ALX Oncology focuses on immuno-oncology, developing therapies to block the CD47 checkpoint pathway, with its lead candidate ALX148 showing promising clinical results.

BURLINGAME, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in a fireside chat at H.C. Wainwright’s Global Life Sciences Conference, being held virtually on March 9-10, 2021.

The prerecorded fireside chat will be available on Tuesday, March 9, 2021 at 7:00 a.m. Eastern Time here and can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 30 days following the presentation date.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML. For more information, please visit ALX Oncology’s website at www.alxoncology.com. 

FAQ

When will ALX Oncology participate in the Global Life Sciences Conference?

ALX Oncology will participate in the Global Life Sciences Conference on March 9-10, 2021.

What time will ALX Oncology's prerecorded fireside chat be available?

The prerecorded fireside chat will be available on March 9, 2021, at 7:00 a.m. Eastern Time.

Where can I watch ALX Oncology's fireside chat?

The fireside chat can be watched on ALX Oncology's website under the Investors section.

What is the focus of ALX Oncology's clinical development?

ALX Oncology focuses on developing therapies that block the CD47 checkpoint pathway.

What is ALX148?

ALX148 is ALX Oncology's lead product candidate, designed to block CD47 and is in clinical development for various cancer treatments.